Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Diagnos Inc V.ADK

Alternate Symbol(s):  DGNOF

Diagnos Inc. is a Canadian company, which is engaged in early detection of critical health problems based on its FLAIRE artificial intelligence (AI) platform. FLAIRE allows for quick modifying and developing of applications, such as computer assisted retina analysis (CARA). CARA’s image enhancement algorithms provide sharper, clearer and easier-to-analyze retinal images. CARA is a tool for real-time screening of large volumes of patients. It provides software-based services to assist health specialists in the detection of diabetic retinopathy and other eye-related pathologies. Its geographical areas include Canada, the United States of America, Mexico, and Chile. The Company’s subsidiaries include Diagnos Internacional SA de CV and Diagnos Healthcare (India) Private Limited.


TSXV:ADK - Post by User

Bullboard Posts
Comment by ZigZagon Jan 27, 2018 1:34am
213 Views
Post# 27445971

RE:Monthly site update

RE:Monthly site update
ashford wrote: Going to be interesting their monthly update of current patients under care that should clear a few things up if they do it for January. Gotta love the research when one does not even know how many shares they own.


It will be interresting to see that number, but don't forget, it represent the number of patients under Diagnos care, not the number of screening done since the beginning of the company.  So, a patient is count only once at its first screening of its life, not at its next screenings later.   That means for the Mexico contract that all 106000 patients screened last year won't be counted this year even if Diagnos is paied for the screening.   And then, the January, February, March counters could not reflect the revenu of diagnos during the 4th quarter, if they start to screen mainly last year clients before the remaining of the 320000 clients of the contract.
Bullboard Posts